BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare ...
NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England. The Scottish ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven
Feedback